Re-Vana Hauls in $11.9M Series A

ExSight is pleased to announce our participation in Re-Vana Therapeutics, Ltd’s $11.9 million Series A financing led by Visionary Ventures. The oversubscribed Series A represents a critical milestone in the company’s development. The proceeds will advance the development of Re-Vana’s proprietary photo-crosslinked EyeLief®, EyeLief-SD™, and OcuLief® biodegradable technologies for the delivery of biologics and enable the company’s operational and development team expansion. This is a testament to the Re-Vana team's dedication and their collective achievements over the last few years.

The clinical need for Re-Vana’s technology only grows with each day as more patients require existing anti-VEGF intravitreal injections and new therapeutic modalities for the treatment of a broader range of ophthalmic diseases approach regulatory approvals. We’re eager to see the Re-Vana team continue to advance this vital technology and are grateful to the Visionary team and other investors for their continued commitment to the company. 

Read the Full Press Release.

ExSight partners Firas, Michael, and James with Re-Vana’s CEO Michael O’Rourke after receiving the ‘Retina Innovation Award’ in Drug Delivery at the 2022 OIS Retina Summit.